-
Safety concerns associated with various types of statins: a disproportionality analysis of the FAERS databas
Author: Zeng, Yi; Tian, Xiaona; Jiang, Jiazhen; Pan, Wenhao; Liu, Bingshuo; Dai, Dandan; Zhou, Lisi; Zeng, Wenling; Chen, Yizhen; Liu, Jiaming
Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2026.2656375
-
Risk of active tuberculosis and herpes zoster with tumor necrosis factor inhibitor treatment in adults with autoimmune disease conditions: a systematic trial sequential analysis of randomized placebo-controlled clinical trial
Author: Okoli, George N.; Cowling, Benjamin J.; Askin, Nicole; Harper, Diane M.; Van Caeseele, Paul
Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2026.2642872
-
Direct oral anticoagulants combined with antiplatelet in the treatment of acute coronary syndrome and atrial fibrillation patients undergoing percutaneous coronary intervention or complicating acute coronary syndrome: a systematic review and meta-analysi
Author: Bai, Lexie; Lin, Shuyun; Liu, Delong; Zhang, Bingbing; Liu, Lili; Zhao, Guojun
Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2596236
-
Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS databas
Author: Dong, Xiaomin; Guo, Guimu; Zhou, Jintuo; Chen, Tingting; Niu, Peiguang; Zeng, Xiaoping; Pan, Ruoxuan; Zhang, Jinhua
Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2026.2618005
-
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting syste
Author: Zhang, Ying; Tong, Shuhua; Wan, Li
Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2499219
-
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS databas
Author: Zhang, Si-Han; Xu, Jin-Zhou; Zeng, Na; Xia, Zhi-Yu; Miao, Lin-Tao; Zhang, Ci; Wang, Shao-Gang; Xia, Qi-Dong
Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2496434
-
Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR database
Author: Kan, Jingjing; Chen, Yechao; Gu, Qiaoling; Hu, Na; Qiao, Yanli; Chen, Yawen; Chen, Dayu; Zhang, Haixia
Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2517232
-
Comprehensive post-marketing safety analysis of tildrakizumab: insights from the FDA adverse event reporting syste
Author: Zhao, Kaidi; Xiao, Shengxiang; Zhao, Yang; Tu, Chen
Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2520422
